Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

v3.21.1
Stock-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Fair Value of Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model

Under the 2019 Plan, the fair value of the Baudax Bio options was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions:

 

 

 

 

March 31,

 

 

 

2021

 

 

2020

 

Expected option life

 

5.5 years

 

 

6 years

 

Expected volatility

 

75.68%

 

 

72.85%

 

Risk-free interest rate

 

0.68%

 

 

0.46%

 

Expected dividend yield

 

 

—

 

 

 

—

 

 
Summary of Stock Option Activity

The following table summarizes Baudax Bio stock option activity during the three months ended March 31, 2021:

 

 

 

Number of

shares

 

 

Weighted

average

exercise

price

 

 

Weighted

average

remaining

contractual life

Balance, December 31, 2020

 

 

2,284,298

 

 

$

3.10

 

 

9.1 years

Granted

 

 

994,877

 

 

$

1.28

 

 

 

Expired/forfeited/cancelled

 

 

(101,852

)

 

$

1.76

 

 

 

Balance, March 31, 2021

 

 

3,177,323

 

 

$

2.58

 

 

8.6 years

Vested

 

 

429,292

 

 

$

4.47

 

 

5.4 years

Vested and expected to vest

 

 

3,177,323

 

 

$

2.58

 

 

8.6 years
Summary of RSUs Activity

The following table summarizes Baudax Bio RSUs activity during the three months ended March 31, 2021:

 

 

 

Number of

shares

 

Balance, December 31, 2020

 

 

991,012

 

Granted

 

 

265,046

 

Vested and settled

 

 

(87,509

)

Expired/forfeited/cancelled

 

 

(31,562

)

Balance, March 31, 2021

 

 

1,136,987

 

Expected to vest

 

 

1,136,987